A review of the literature concerning the effects of traditional antirheumatic drugs on cytokines and the cytokine and anticytokine approaches already used in the therapy of rheumatoid arthritis (RA) is presented. Many antirheumatic drugs are capable of cytokine modulation in vitro. Corticosteroids inhibit the transcription of a broad spectrum of genes including those encoding monocyte, T cell-derived cytokines and several hemopoietic growth factors, whereas drugs such as cyclosporin A and D-penicillamine interfere with T cell activation more specifically by suppressing interleukin 2 (IL-2) production. The in vivo effects of drug therapy on cytokines in RA patients are less well established. Gold compounds reduce circulating IL-6 levels and the expression of monocytederived cytokines, such as IL-1, tumor necrosis factor (TNF), and IL-6, in the rheumatoid synovium. Decreases in circulating IL-6, soluble IL-2 (slL-2R), and TNF receptors and in synovial fluid IL-1 levels have been reported with methotrexate. Reductions in circulating IL-6 and slL-2R concentrations have also been observed with cyclosporin and corticosteroids, whereas azathioprine reduces IL-6 but not $IL-2R. Studies on sulfasalazine are conflicting and the in vivo effects of D -penicillam ine and antimalarials have not been studied yet. Interferon 7 therapy is not effective in RA but may prove a useful antifibrotic for systemic sclerosis. Colony stimulating factors improve the granulocytopenia associated with Felty's syndrome or drug toxicities but can induce arthritis flares and should be reserved to treat infectious complications. Promising results are being obtained with selective antagonism of TNF and IL-1 in RA, and combinations of anticytokine strategies with traditional antirheumatic drugs have been already envisaged. These should preferably be based in a broader knowledge of the effects of antirheumatic agents on the cytokine network. Semin Arthritis Rheum 25:234-253, Copyright © 1996 by W.B. Saunders Com pany INDEX WORDS: rheumatoid arthritis; antirheumatic drugs; cytokines. T HE PHARMACOLOGICAL agents used in the therapy of rheumatoid arthritis (RA) have been traditionally subdivided into
pressive agents. Many SAARDs interfere with cellular metabolic processes and have nonspe cific anti-inflammatory, immunoregulatory, and anti-angiogenic effects, which may contribute to their efficacy or toxicity, but usually do not fully explain their therapeutic effects.
Cytokines are a complex family of peptides with specific receptors that mediate intercellu lar communication and play a crucial role in immunologic and inflammatory reactions. The evidence implicating cytokines in the pathoge nesis of RA and other autoimmune diseases has had repercussions on the treatment of these disorders. It is known that several drugs, inclu ding SAARDs, modulate the cytokine network. This may be important because cytokines con trol the proliferation, activation, traffic, and homing of immunocompetent cells in the joint, as well as the growth and function of synovial, cartilage, bone, and endothelial cells. Further more, some circulating cytokines or cytokine receptors may act as markers of disease activity or immune activation and prove useful in moni toring the effects of treatment. Finally, and more importantly, selected cytokines and anticy tokines are being used to treat RA, and the search for pharmacological agents with specific cytokine-suppressive properties has just begun. In this report, we review the modulatory proper ties of several SAARDs and other pharmacologi cal agents on the cytokine network and summa rize the clinical experience with cytokine and anticytokine strategies in the treatment of RA.
THE CYTOKINE NETWORK IN RA
A detailed review of the cytokine network is beyond the scope of this paper. Therefore only relevant aspects will be briefly mentioned. Ac cording to their biological effects, cytokines can be classified as proinflammatory or anti-inflam matory, fibrotic, growth and chemotactic factors ( Table 1) . Such a functional classification is an oversimplification because cytokines are charac terized by pleiotropism (one cytokine possesses multiple functions), overlap (several cytokines share similar effects), and mutual regulation. Nevertheless, by considering their function, bet ter insight into the links between cytokines and other processes involved in RA and their poten tial consequences for therapy can be gained. Because of their systemic and local effects, interleukin 1 (IL-1) and tumor necrosis factor a (TNFa) are the prototypes of pro-inflammatory cytokines.2 Compelling evidence from in vitro studies and experimental arthritis models shows that tissue destruction and joint inflammation are independently regulated by IL-1 and TNF and that these mediators orchestrate the ar thritic process.2» 3 The IL-1 "family'' consists of three related peptides: IL-la, which is primarily cell bound, IL-1(3, which is primarily secreted, and the IL-1 receptor antagonist (IL-IRa). These three molecules are each capable of binding to the membrane receptors, but only IL-la and (3 are biologically active. The IL-IRa occupies the receptor but does not activate signal transduction, and therefore it acts as a competitive IL-1 inhibitor.4 There are two types of IL-1 receptors. Type I (IL-1RI) mediates signalling activity and has a higher affinity for IL-la and IL-IRa, whereas type II (IL-1RII) is a decoy receptor, which lacks signalling capacity and has a higher affinity for IL-1 p.5 Membranebound and soluble forms of the IL-1RII decoy receptor and the IL-IRa together represent natural mechanisms for counteracting the poten tially toxic role of IL-1 in vivo.
TNFa and the related lymphotoxin (TNFp) bind to two forms of membrane receptors, type 1 or p55 and type 2 or p75, which are active in signal transduction, and can be cleaved from the cell membrane yielding soluble forms (sTNFR). The sTNFRs behave as endogenous antagonists by binding TNFa, preventing it from attaching to the membrane receptors, but may also func tion as carrier molecules that preclude TNF degradation. 6 IL-1, IL-IRa, and TNFa are present in the rheumatoid synovial membrane and can be detected in plasma and in synovial exudates of RA patients together with soluble forms of both TNFR and type II IL-1R. Compared with IL-IRa and sTNFR, the concentrations of IL-1 and TNF in biological fluids are low but this excess of antagonists may not be sufficient to block the activity of IL-1 and TNF completely. 2 IL-1 and TNFa are arthritogenic in several animal models, and antagonizing their effects reduces the severity, or even prevents arthri tis.2'3 Moreover, these cytokines occupy a high position in the cytokine hierarchy because they stimulate the production of each other and of many proinflammatory cytokines including granulocyte-macrophage colony-stimulating fac tor (GM-CSF), IL-6, leukemia-inhibitory fac tor, IL-8 and other chemotactic factors.7 It is therefore not surprising that ongoing anticyto kine strategies for RA are primarily focused on suppressing the actions of IL-1 and TNF.
IL-6 stimulates B and T cell differentiation and activation, as well as immunoglobulin pro duction, and shares proinflammatory activities with IL-1, TNF, and colony stimulating factors. However, IL-6 is not arthritogenic, does not induce local prostaglandin-E2 or collagenase production, and is anti-inflammatory by promot ing the acute phase reaction, upregulating metalloprotease inhibitors,7 suppressing IL-1 and TNF synthesis in vitro, and inducing IL-1 and TNF endogenous antagonists in vivo.8 More over, IL-6 is readily detected in biological fluids and may be a useful marker of disease activity.
Several other cytokines, including colonystimulating and growth factors, chemotaxins, and the leukemia-inhibitor factor (LIF), are also present in the rheumatoid synovial mem brane and are thought to perpetuate the ongoing inflammation by stimulating cell recruitment and activation.7
In contrast to the abundance of monocytederived cytokines, T cell products are scant in the inflamed joint,9'10 which has led to specula tion about the role of T cells in RA. T helper cells can be divided into Thl (secreting IL-2 and IFN7 ) and Th2 subsets (secreting IL-4 and IL-5). Other cytokines such as transforming growth factor (B (TGF(3), IL-10, and IL-13 are not confined to these subsets and are also produced by non-T cells.11*12 IL-2 is implicated in the activation and proliferation of T, B, and natural killer (NK) cells, whereas IFN7 induces the expression of class II HLA and adhesion molecules, activates macrophages, lymphocytes, and NK cell activity and has antiproliferative and antifibrotic effects. Lymphocytes from RA patients defectively produce IL-2 and IFN7 and are hyporresponsive to IL-2, which could ac count for the low proliferative responses to mitogens and delayed type hypersensitivity in RA. Because of its immunostimulatory proper ties, IL-2 has been used in the therapy of malignancies, whereas several studies have ex amined the effects of IL-2 inhibition13 and IFN7 therapy in RA.14 In contrast with the low levels of IL-2, high concentrations of its soluble receptor (sIL-2R) have been detected in several autoimmune diseases including RA. These are considered to reflect lymphocyte activation and may be useful in monitoring disease activity. 15 Finally, cytokines such as IL-4, IL-10, IL-13, and TGFp are considered anti-inflammatory because they inhibit the production of proinflammatory cytokines such as IL-1 and TNF and upregulate their inhibitors.12,16 These anti inflammatory cytokines are being tested in ani mal models and may find therapeutic applica tion in human autoimmune diseases.
EFFECTS OF SAARDS AND OTHER ANTIRHEUMATIC DRUGS IN CYTOKINE MODULATION
Our knowledge of the cellular and soluble mediators of inflammation has advanced our understanding of the mode of action of SAARDs in RA. Knowing that cytokines play a key role in the cascade of inflammatory responses has stimulated research on the effects of antirheu matic drugs on these mediators. Several in vitro studies and observations in animal models and in patients treated with SAARDs suggest that some of these agents have cytokine-modulating properties. The present section summarizes the literature on several SAARDs, corticosteroids, and other drugs with "cytokine suppressive" properties.
Antimalarials
The antimalarial agents hydroychloroquine (HCQ) and chloroquine (CQ) are quinoline derivatives that exert a variety of effects on immunocompetent cells. These agents accumu late in lysosomes, inhibit several enzymes, and interfere with the function of monocyte-macro phages, which may represent their main mode of action. Early studies showed that HCQ and CQ inhibit the cartilage degradation induced by IL-1.17 More recently, it was shown that thera peutic concentrations of HCQ suppressed the production of IL-1 and IL-6 by monocytes, probably acting at a posttranscriptional level.18'19
The effects of these drugs on TNFa production is more controversial, although combinations of HCQ with sulfasalazine inhibit IL-1 and TNF production synergistically,18'19 HCQ does not alter either IL-8 gene expression or synthesis by endothelial cells and monocytes20 or the produc tion of IL-2, IL-4, or IFN7 by T cells.18 How ever, the drug inhibits IL-6 synthesis by T cells, suggesting a selective effect of HCQ on some proinflammatory cytokines (IL-1 and IL-6).18 The effects of HCQ therapy on cytokines in RA have not been investigated, but Wallace et al21 observed lower circulating concentrations of IL-6 and sIL-2R in systemic lupus erythematsus (SLE) patients treated with HCQ than in those receiving only corticosteroids or no therapy. In a prospective study by the same authors, signifi cant decreases in serum IL-6 levels occurred after 6 and 12 weeks of treatment with HCQ, though sIL-2R concentrations remained un changed.22 This seems to confirm the relative lack of effect of HCQ on T cell activation.
CQ and HCQ have similar effects on mono cytes, although the former may have additional effects on T cells. CQ inhibits monocyte produc tion of IL-1,23 TNFa, and IL-624 and acts syner gistically with cyclosporin in suppressing IFN7 production by T cells.25 CQ therapy does not affect IL-1 production in animal models of adjuvant arthritis26 or haemorrhagic shock but inhibits TNF, IL-6 and prostaglandin release in the latter.27
Gold Compounds
Gold compounds modulate the functional activities of virtually every immunocompetent cell, but inhibition of mononuclear phagocyte function may be of paramount importance. This is supported by the suppressive action of these agents on the production or activity of monocytederived proinflammatory cytokines.
Most in vitro studies have shown that gold sodium thiomalate (GST) and auranofin (AF) inhibit the synthesis of IL-1 by monocytes28'32 and act synergistically when combined.19 Gold compounds also antagonize some of the biologi cal effects of IL-1,28» 33'34 and therapy with these agents decreases IL-1 production in adjuvant arthritis.26,35 Danis et al studied the production of IL-1 by monocytes from RA patients treated with GST. Patients considered "high IL-1 pro-ducers" at baseline had transient clinical im provement associated with decreases in IL-1 secretion, whereas "low producers" had a bet ter clinical response and an increase in IL-1 secretion during therapy.36 The authors sug gested that IL-1 production before treatment might be predictive of the clinical response to GST, but several confounding factors, including the use concomitant medications, render this study inconclusive.
Gold does not alter IL-IRa synthesis by normal monocytes32 although increases have been reported in patients with RA.37 Further studies should elucidate whether gold therapy induces a beneficial shift in the IL-1/IL-lRa balance.
Gold compounds may modulate other proinflammatory cytokines besides IL-1. GST inhib its the production of IL-6, but not of TNF, by monocytes,32 suppresses the synthesis of IL-8 and monocyte chemoattractant protein (MCP-1) by rheumatoid synoviocytes,38 and interferes with the production of IL-8 by monocytes and endothelial cells.20» 39 AF, however, inhibits the production of TNFa by monocytes,40 and sev eral effects of this cytokine on neutrophils.41,42 Serial studies in patients with RA receiving chrysotherapy have reported reductions in circu lating IL-6 levels,43» 44 monocyte production of IL-6,45 and, interestingly, cytokine expression in the synovial membrane as recently demon strated by Yanni et al46 Using sequential syno vial biopsies, the authors observed a striking decrease in the expression of monocyte-derived cytokines, including IL-1 (3, IL-la, IL-6, and TNFa, and in the number of infiltrating mono cytes and macrophages after 12 weeks of treat ment with GST, whereas the number of T and B cells remained unchanged.46 Whether such re duction in monocyte infiltration results from systemic effects, like inhibition of myelopoiesis,47 or from a local action of gold is unknown, but these results indicate that the monocytemacrophage is the principal target cell for gold compounds. Nevertheless, T cell proliferation and activation and cytokine production are also affected by these drugs at least in vitro. Gold compounds inhibit T cell proliferation induced by mitogens, antigens,48» 49 and IL-250'51 and sup press the synthesis of IL-2 and the expression and release of IL-2R by activated T cells at a transcriptional level.49 Some of these effects may require low intracellular glutathione con centrations.52 The effect of gold on IFN*y produc tion is controversial,53» 54 but GST inhibits sev eral IFNy activities such as the induction of class II HLA expression in monocytes55 and endothelial cells.51 This, together with the inhi bition of endothelial cell proliferation56 and expression of adhesion molecules by gold com pounds,57 may result in decreased angiogenesis and cell recruitment in the joint.
Chrysotherapy normalizes depressed IL-2 pro duction in adjuvant arthritis35 and patients with pemphigus vulgaris.58 In contrast, circulating sIL-2R levels in RA remain unchanged after 24 weeks of gold therapy, despite clinical improve ment,59*61 and only one study reported lower sIL-2R levels in patients with clinical remission than in those with active disease after prolonged treatment.60 It seems, therefore, that despite the inhibitory effects of gold on T cells in vitro, chrysotherapy for RA does not affect T cell infiltration in the joint46 or lymphocyte activa tion evidenced by sIL-2R, at least in the short term.
D-Penicillamine
D-penicillamine and the related drug bucillamine, are structural analogues of cysteine, which, in contrast to gold and antimalarials, may pre dominantly affect lymphocytes (especially T helper cells) without altering macrophage func tion. Whether therapy with these drugs results in cytokine modulation in RA has not been assessed, but available in vitro studies corrobo rate this hypothesis.
The drugs' effect on T cell function is medi ated by their capacity to generate hydrogen peroxide in the presence of copper salts. This results in a direct inhibition of T cell activation and production of IFNy and IL-2, and indirectly in decreased immunoglobulin synthesis by B lymphocytes. 62, 63 Initial in vitro studies suggested that dpenicillamine might decrease the production of monocyte products with IL-l-like activity.64 Later it was shown that IL-1 synthesis and bioactivity are suppressed only with high concentrations of the drug33; however, therapeutic concentrations do not alter the production of either IL-123» 30» 65 or TNF19 by human monocytes. Moreover, therapy with D-penicillamine does not inhibit IL-1 production in the adjuvant arthritis model.26'66 D -penicillam ine blocks the binding of IL-ip to a-2-macroglobulin, an acute phase protein that may function as carrier for IL-1 and other cytokines.67 This dissociating effect is not specific for IL-1,68 and its relevance for the therapeutic effect of the drug is speculative. In the presence of copper, D-penicillamine and other thiol compounds inhibit spontaneous and IL-l-induced fibroblast proliferation. This is due to the production of hydrogen peroxide rather than suppression of IL-1 synthesis.69 D-penicillamine inhibits the proliferation and IL-8 gene expression and synthesis by endothe lial cells,20 and decreases neovascularization in vivo. 70 These antiangiogenic and antifibrotic properties may be important for therapeutic efficacy in RA and systemic sclerosis. It has been suggested that bucillamine is superior to D -penicillam ine in treating RA,71 possibly be cause of its additional immunosuppressive ef fects. In vitro, both drugs inhibit T cell function, including IL-2 and IFN7 production, in the presence of copper,72 but only bucillamine forms an intramolecular disulphide and inhibits B cell function whether or not copper salts are pre sent.62'72 This effect is not due to decreased IL-6 production by B cells. 62 Furthermore bucilla m ine-, like D -penicillam ine, does not affect IL-1 production by human monocytes.30'65
Sulfasalazine
Sulfasalazine is an azo compound of sulfapyridine and 5-aminosalicylic acid. Sulfapyridine seems to be the active component in RA, though sulfasalazine itself might also have antirheumatic properties. The exact mechanism of action of this drug remains also unclear despite its multiple anti-inflammatory and immunoregulatory effects.
In vitro, sulfasalazine inhibits the production of IL-ip and TNFa by monocytes19'30'73-75 and may suppress the binding of TNFct to its recep tors. 76 Neither the production45'74,77 nor the activity of IL-6 are markedly altered by sulfasala zine.78 However, the drug down-regulates the synthesis of IL-2 and IFN7 by T cells,79,80 which may explain its inhibitory effect on lymphocyte proliferation and antibody production. More over, sulfasalazine inhibits the proliferation as well as IL-8 gene expression and synthesis20 in endothelial cells, which may account for its antiangiogenic effects. Interestingly, most of the effects of sulfasalazine on cytokines and immunoregulation are not shared by its metabolites, which suggests that the parent compound pos sesses therapeutic effects.
Studies on the effect of sulfasalazine therapy on circulating cytokines in RA have yielded conflicting results. In a 6-month, placebocontrolled study, Danis et al77 observed decreases in IL-1 a, IL-1 (3, and TNFa but unchanged IL-6 concentrations during sulfasala zine therapy,77 whereas other authors reported no changes in IL-1 (3 and TNFa levels81 and decreases in serum concentrations and mono cyte production of IL-6.45,81*82 Circulating sIL-2R concentrations did not change after 12 weeks of therapy with sulfasalazine in several stud ies.61'81*82 The number of patients in these stud ies generally were too small to draw definitive conclusions and the effects of sulfasalazine therapy need further investigation.
Combinations of SAARDs are increasingly used to treat RA and there are in vitro data suggesting that some of these combinations suppress cytokine production in a synergistic manner, 19 In an open study conducted in our center, the combination of sulfasalazine with methotrexate proved clinically superior to methotrexate alone.83 Serial cytokine measure ments showed decreases in IL-6 and sIL-2R levels with both therapies, but the concentra tions of sTNFR and the production of IL-1 (3 and IL-IRa by monocytes fell only in patients treated additionally with sulfasalazine. These results suggest an additional or specific sulfasala zine on these cytokines84 and encourage further studies on the effects of other SAARD combina tions.
Methotrexate
Intensive efforts have been made to elucidate the mechanism of action of methotrexate. Be cause of its antifolate effect, methotrexate may impair DNA, RNA, and protein synthesis, in hibit transmethylation reactions and polyamine synthesis, and stimulate adenosine release. Moreover, the drug can inhibit 5-lipoxygenase activity and has modulatory effects on cyto kines.85
Methotrexate inhibits some biological activi ties of IL-1 including the proliferation of thymo cytes86'87 and synovial fibroblasts but does not affect the production of collagenase, prostaglan din E, hyaluronic acid, or metalloprotease inhibi tors induced by IL-1.88'89 This suggests that the drug antagonizes the proliferative but not the secretory activities of IL-1.88 The suppression of IL-1 bioactivity by methotrexate is due to its antifolate effect because it can be reversed by folinic acid,87 although binding of methotrexate to IL-1, which has structural homology to dihy drofolate reductase (DHFR), or receptor downregulation have been also proposed to explain this effect.90 Methotrexate therapy decreases the production of IL-1 in adjuvant arthritis,91'93 although this has not been consistently observed in RA. Two studies have assessed the effect of a single dose of methotrexate on monocyte IL-1 (3 production: Segal et al86 reported no changes in 9 patients treated with methotrexate for vari able periods of time, whereas we observed significant decreases after the first methotrexate dose, but not in patients treated for longer than 1 year who already had lower IL-1|3 production and less active disease. 94 In another study, Chang et al95 reported decreases in IL-1 produc tion in 4 of 8 patients after 6 weeks of methotrex ate therapy.95 These studies suggest that if MTX down-regulates IL-1 production the effect oc curs in the early phase of treatment. To test this hypothesis, we monitored 26 patients treated with methotrexate for 24 weeks. Some decrease in IL-1 production occurred after 4 weeks, but the effect was not progressive and measure ments after 24 weeks were not significantly lower than those at baseline.84 Therapy with methotrexate did not alter circulating IL-1 (3 concentrations in this and another study,84» 95 but decreases in serum96 and in synovial fluid con centrations of IL-1(B have been described.97 Taken together, methotrexate may inhibit the proliferative effects of IL-1, and decrease mono cyte IL-1 production in the short term in certain patients, although this effect is not sustained and unlikely explains the long-term efficacy of methotrexate. Further investigation is needed to elucidate whether therapy with methotrexate decreases the production of IL-1 in the joint.
In-vitro, methotrexate inhibits IL-6 but not TNF bioactivity86 and decreases the production of IL-8 by monocytes.39 The synthesis of IL-8 by endothelial cells20 or RA synoviocytes38 is not affected by the drug. Treatment with methotrex ate reduces circulating IL-6,84,96'98*99 IL-8,96 and p55 soluble TNF receptor (sTNFR) concentra tions98 in patients with RA but does not affect circulating levels84,98 or monocyte production of TNFa.84'94 Decreases in IL-6, IL-8, and p55 sTNFR levels probably reflect clinical improve ment and are not a specific effect of methotrex ate. Several studies have investigated the effects of methotrexate on T cell-derived cytokines. In vitro this drug enhances the cytotoxic100 and proliferative86 effects of IL-2 and the produc tion of this cytokine by lymphocytes.101 Metho trexate therapy normalizes the defective produc tion of IL-2 in the adjuvant and streptococcal cell wall arthritis models.91,93 Lymphocyte IL-2 synthesis increases after a single dose of metho trexate in patients with RA102 and in patients receiving the drug for longer periods.96,103 Kremer et al96 reported increases in serum IL-2 concentrations during treatment with methotrex ate,96 and decreases associated with disease flares 4 weeks after withholding the drug.104 The defective IL-2 production in RA might be due to excessive polyamine production,105 which is inhibited by methotrexate.106 This effect could explain the enhanced IL-2 production observed during methotrexate therapy.107 In contrast with this up-regulation of IL-2, treatment with metho trexate reduces the circulating sIL-2R levels in patients with RA84,98,99'108 and juvenile chronic arthritis.109 This effect does not predict re sponse to treatment108 but rather reflects clini cal improvement. 98 Recent studies suggest that methotrexate may not only upregulate Thl-cytokines, like IL-2, but also may downregulate Th2-derived cyto kines. Taylor et al110 observed an increased mRNA expression of IL-4 and IL-10 in mono nuclear cells from RA patients compared with healthy controls. Treatment with methotrexate reduced IL-4 and IL-10 but enhanced IFN7 expression in patients with RA.1U ) Consistent with these effects, Kremer et al96 reported decreases in serum IL-4 during methotrexate therapy and increases in circulating IL-4 levels associated with disease flares after stopping treatment. 102 The effects of methotrexate on IL-2, IL-4, and IL-10 are puzzling because they suggest a shift in cytokine expression towards a "pro-inflammatory" pattern.
Azathioprine
The purine analogue azathioprine is con verted in 6-mercaptopurine (6-MP) which fol lows pathways similar to endogenous purines and is incorporated into DNA and RNA. The cytotoxicity of azathioprine is unlikely to ac count for its therapeutic efficacy in RA, but the levels of endogenous purine enzymes respon sible for its metabolism may influence its toxic ity. 111 In vitro studies suggest that azathioprine does not alter IL-2 production,112,113 whereas both azathioprine and 6-MP inhibit IL-6 bioacti vity.78 Studies concerning the effect of therapy with azathioprine on cytokines in patients with RA are scant. In a 48-week trial of azathioprine versus methotrexate, we observed no significant changes in the circulating concentrations of either TNFa or the soluble TNF and IL-2 receptors during treatment with azathioprine. Decreases in IL-6 concentrations reflected clini cal improvement and were not specific to the drug.98 In a smaller study, Crilly et al114 reported no changes in either circulating sIL-2R levels or in the production of IL-6 by monocytes after 24 weeks of azathioprine therapy.
Cyclosporin A
Cyclosporin A is an immunosuppressive agent that specifically interferes with T cell activation. Complexes of cyclosporin A with its specific receptor, cyciophilin, bind to and block the activity of calcineurin, preventing the activation of transcription factors involved in cytokine gene expression.115 The major effect of cyclo sporin A is the suppression of T cell activation, which is due to inhibition of the transcription and synthesis of IL-2 and the expression of receptors for IL-2 in lymphocytes.115'116 This results in secondary inhibition of B lymphocyte, natural killer (NK) cell and macrophage activi ties. Besides its effect on IL-2, cyclosporin A inhibits the transcription of IL-3, IL-4, IL-5, IFN7 ,116 and TNFa117 in T cells. The synthesis of IL-1 by monocytes is not affected by cyclo sporin A,23 although the drug may antagonize some of this cytokine's effects in bone and cartilage.116 Linder certain conditions, cyclo sporin A decreases monocyte TNFa produc tion. [116] [117] [118] Decreases in the number of circulating cells bearing the IL-2R119 and in circulating sIL-2R and IL-6 concentrations120,121 have been re ported in RA patients treated with cyclosporin A. Decreases in sIL-2R levels associated with clinical improvement also have been observed during cyclosporin A therapy for Crohn's dis ease122 but not in systemic sclerosis.123 Corticosteroids Glucocorticoids (GCs) affect virtually every cellular and humoral mechanism involved in inflammation and immune response, including cytokines. The mechanism of action of GCs is complex but involves regulation of gene tran scription. GCs form complexes with specific cytoplasmic receptors, which are translocated to the cell nucleus. Interestingly, mononuclear cells from patients with RA shown a low GC receptor density, although this does not result in GC resistance. 124 The binding of GC-receptor complexes to regulatory elements of DNA re sults in either positive or negative regulation of gene transcription. GCs interfere with cytokine production not only by suppressing their tran scription, but also by decreasing messenger RNA stability and affecting other posttranscriptional events.125-128 This inhibits the synthesis of proinflammatory and chemotactic cytokines such as IL-1, TNFa, IL-6, IL-8, and monocyte chemo tactic and activating factor (MCAF), and hemo poietic growth factors such as IL-3 and GM-CSF.20'38'128'132 In addition, GCs interfere with T cell activation by down-regulating the gene expression of IL-2 and IL-2R, inhibit the produc tion of IL-4 and IFN7 by lymphocytes,133'134 and induce IL-1 and IL-6 receptor expression in some cells.135-137 In vitro experiments have shown that the combination of GCs with IL-4 sup presses the synthesis of IL-1 and TNFa by monocytes138 and synovial tissue139 synergistically, which may find applications in future therapies.
Several studies have provided evidence for a modulatory role of GC therapy on cytokine production or release in vivo. In humans, therapy with GCs attenuates the toxicity induced by IL-2 and lymphokine activated killer cells, OKT3, and experimental endotoxinemia by re ducing the release of TNFa, IFN7 , and IL-2 in the circulation.140'142 These drugs inhibit IL-4 and IL-5 expression by bronchoalveolar cells143 and monocyte TNF production144 in asthmatic patients and reduce circulating IL-6 levels in patients with polymyalgia rheumatica and giant cell arteritis. 145 In RA, circulating levels of IL-6, IL-8, and sIL-2R146 and the production of IL-1 by monocytes147 decrease significantly after pulse therapy with high-dose corticosteroids, and re ductions in sIL~2R148 and TNFa149 concentra tions are associated with improvement during treatment with low-dose GCs.
Other Drugs
The number of pharmacological agents with potential antirheumatic and cytokine-modulat ing activities is too long to be fully enumerated. Several drugs used for other indications were discovered, by chance, to have antiarthritic effects. Among these agents, thalidomide, a sedative, and pentoxifylline, a phosphodieste rase inhibitor used for peripheral vascular disor ders, are worthy of mention because of their TNFa-suppressive activities. Thalidomide inhib its TNFa production, neutrophil chemotaxis, and superoxide generation, but its use in RA has been limited because of the drug's toxic ity.150 Pentoxifylline decreases TNFa production in vitro and in vivo151 and has anti-inflammatory, immunomodulatory, and anti-fibrotic proper ties. In an open, 3-month trial, performed in patients with severe RA refractory other thera pies, additional treatment with pentoxifylline resulted in clinical improvement. TNF produc tion remained unchanged after 3 days of treat ment but was, unfortunately, not measured thereafter.152
More selective cytokine inhibitors already used in clinical trials for RA include IX 207-887 and the dual cyclooxygenase/lipoxygenase in hibitor tenidap. IX 207-887 inhibits IL-1, IL-6, and superoxide production and is effective in animal arthritis. A placebo-controlled study in RA reported improvement in clinical and labo ratory variables in patients treated with IX 207-887, although adverse reactions were fre quent.153 Tenidap inhibits the synthesis of IL-1, IL-6, and TNFa by human monocytes and rheumatoid synovium154-155 and decreases T cell proliferation and IFN7 synthesis.156 Further more, the drug inhibits metalloprotease produc tion by chondrocytes exposed to IL-1,157 bone resorption induced by IL-1 and TNF,158 and the expression of HLA class II antigens in synovio cytes exposed to IFN7 . 159 Patients with RA receiving tenidap show reductions in acute phase reaction and circulating IL-6 and sIL-2R concentrations.160-161
Several immunoregulatory agents under cur rent investigation for treating autoimmune dis eases may affect cytokine production. These encompass drugs with immune-enhancing ef fects (levamisole, tilomisole and imuthiol) inhibi tors of nucleotide synthesis (mycophenolate, brequinar, and mizorbine) and immunosuppres sive agents (15-deoxyspergualin, leflunomide, FK506, and rapamycin).162'163 Leflunomide, an isoxazol-derivative currently undergoing clinical trials for RA, inhibits lymphokine-dependent T and B cell proliferation and decreases IL-1 and TNFa induced proliferation of RA synovial fibroblasts.164 FK506 and rapamycin are cyclo sporin-related drugs that share structural homol ogy and the same immunophillin receptor but interfere with T cell activation at a different level. Like cyclosporin, FK506 decreases the activity of calcineurin, is a potent suppressor of IL-2 production and receptor expression, and inhibits the transcription of various cytokines (IL-3, IL-4, IL-5, IFN7 , TNFa, 118 and IL-8165). Rapamycin interferes with lymphokine signal transduction without affecting calcineurin activ ity. Both agents are effective in animal arthritis and are being evaluated in patients with autoim mune diseases and organ allografts.
THERAPY WITH CYTOKINES AND ANTICYTOKINES IN RA
Advances in molecular biology have provided new therapeutic approaches for autoimmune diseases. Among the immunomodulators, se lected cytokines such as IFN7 , GM-CSF, and G-CSF have been used to treat RA or its complications and promising results are being obtained with specific antagonists of proinfiammatory cytokines.
The rationale for the use of IFN7 therapy in RA was tenuous, being based on the relative deficiency of this cytokine in the joint and its inhibitory effects on B cells, neutrophils, fibro blasts, and cytokine release. The lack of signifi- Patients were refractory to-and continued metho trexate therapy; improvement in 5/16 patients receiving high dose course; common adverse events, often transaminase elevations Additional methotrexate in 10 patients; lack of effect in 17 patients, less common adverse events; maintained improvement with repeated courses Improvement in tender joint count in the high-dose group Improvement after 7 days, frequent skin reactions at the injection site, 3 patients withdrawn (side effects) improvement most marked with daily dose; frequent skin reactions at the injection site (62%); 25 patients withdrawn (lack of effect [n = 12], adverse events [n = 131) multicenter, placebo controlled trial ongoing To date, IL-1, TNF, IL-6, and IL-2 have been the target of specific anticytokine approaches in RA ( Table 2 ). The experience with anti-IL-2 and anti-IL-6 treatment is limited,171"178 and most attention has been drawn by therapies counteracting the two pivotal mediators TNFa and IL-1.179"187 Initial results suggest that these anticytokine therapies are well tolerated and result in rapid improvement of clinical symp toms and laboratory parameters. Because these effects are transient, repeated administration is necessary. Besides the therapies listed in Table  2 , other approaches, including soluble IL-1 receptors, inhibitors of the specific IL-1 convertase,16 antiinflammatory cytokines such as IL-4, IL-10, and IL-13, and the use of antisense oligonucleotides and gene therapy, are under investigation.
SUMMARY, CONCLUSIONS, AND FUTURE PROSPECTS
The search for evidence that antirheumatic drugs interfere with cytokines is hampered by several problems, not least among those being the difficulty in extrapolating experimental data obtained in vitro to the situation in vivo (or in humans): Some SAARDs alter cytokine produc tion or activity only at drug concentrations that are not attainable during therapy, and most in vitro studies do not take into account the effect of drug metabolites or the complexity of the immune response in vivo. This is exemplified by the bimodal effect of gold compounds on IL-1, IL-2, and IL-8. Although low concentrations of these agents seem to stimulate IL-1 and IL-2 and inhibit IL-8 production, the converse occurs at higher drug concentrations. 19> 20» 31> 52 More over, in the case of IL-2, either stimulation or strong inhibition can be attained with low con centrations of GST depending on the glutathi one content of the cells studied.52 In vitro results, therefore, need to be confirmed by observations in vivo. Experience with animal models has taught us about the arthritogenic potential of cytokines and the effects of therapy with drugs and other anticytokine strategies, but the differences between human and animal arthritis emphasizes the need for human stud ies. Reports on the effects of SAARD therapy on cytokines in RA are relatively scarce and pitfalls include methodological problems, inter individual variations in cytokine concentrations, and most importantly, the need to quantify an increasing number of cytokines, preferably in the joint. Moreover, because SAARDs also modify disease activity in RA, changes in cyto kine concentrations or expression during therapy with these agents may reflect clinical improve ment rather than a specific drug effect.
Despite these problems, some conclusions on the cytokine-modulating effects of antirheumatic drugs can be drawn. First, it seems likely that many effects of antirheumatic agents on inflam mation and immune response are mediated by, or result in, cytokine modulation. Second, the effects of antirheumatic drugs are usually not confined to a single cytokine. Even cyclosporin, considered to downregulate IL-2 gene transcrip tion most specifically, also inhibits the synthesis of other T cell-derived cytokines,116 whereas corticosteroids, have the broadest spectrum of activity and inhibit gene transcription of virtu ally every cytokine gene. Third, in contrast to the usually low levels of IL-1 and TNFa, high concentrations of IL-6, sIL-2R, and sTNFR are present in the circulation and synovial fluid of RA patients, and correlate with several disease activity measures. Therapy with a number of SAARDs and corticosteroids decreases circulat ing IL-6 and sIL-2R concentrations and sTNFR levels apparently decrease with methotrexate given alone or in combination with SASP.84'94 These effects probably reflect clinical improve ment and suggest that IL-6, sIL-2R, and sTNFR may be useful markers of disease activity in RA. Fourth, preliminary evidence suggests that therapy with certain SAARDs may regulate cytokine production by circulating cells and, most importantly, cytokine expression in the joint, as recently shown during gold therapy.46
The most important conclusion from previous studies is that our knowledge of the effects of SAARD therapy on the cytokine network in RA is patchy. Properly controlled, longitudinal stud ies assessing both cytokine concentrations in biological fluids and their expression in the joint during SAARD therapy are needed.
The rheumatologists are familiar with the use of combinations of NSAIDs, SAARDs, and corticosteroids as well as with patients refrac tory to these treatments. This has resulted in a search for novel therapies aimed at interfering with specific sites of immunoregulation, inflam mation, and tissue destruction. The targets envisaged include T cells, antigen presentation, adhesion molecules, metalloproteases, nitric ox ide, and cytokines. Trials with anticytokine therapies have reported rapid but transient clinical benefits in RA and ongoing studies will show whether these effects can be maintained with repeated administration. There is wide clinical experience with SAARD therapy for RA and it is unlikely that novel therapies will supplant these agents in the near future, al though combinations of cytokine-suppressive and traditional therapies offer interesting per spectives. More knowledge on the effect of SAARDs on cytokines is needed before we arrive at selected combinations that comple ment each other's actions and translate this into better treatment for RA. 
